Harmony Biosciences (HRMY) Set to Announce Quarterly Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY) is scheduled to announce its earnings results before the market opens on Tuesday, October 29th. Analysts expect the company to announce earnings of $0.66 per share for the quarter. Harmony Biosciences has set its FY 2024 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.24. The firm had revenue of $172.80 million during the quarter, compared to analyst estimates of $172.53 million. Harmony Biosciences had a return on equity of 22.97% and a net margin of 17.53%. The business’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.56 earnings per share. On average, analysts expect Harmony Biosciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Harmony Biosciences Trading Down 1.3 %

Shares of Harmony Biosciences stock opened at $34.95 on Tuesday. The firm has a market cap of $1.98 billion, a price-to-earnings ratio of 15.13, a PEG ratio of 0.67 and a beta of 0.73. The business has a 50-day moving average price of $36.44 and a 200-day moving average price of $32.87. The company has a quick ratio of 3.09, a current ratio of 3.13 and a debt-to-equity ratio of 0.32. Harmony Biosciences has a twelve month low of $18.79 and a twelve month high of $40.60.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on HRMY shares. Needham & Company LLC restated a “buy” rating and set a $52.00 price objective on shares of Harmony Biosciences in a research report on Wednesday, October 2nd. Raymond James reiterated an “outperform” rating and issued a $40.00 price target on shares of Harmony Biosciences in a research report on Thursday, October 10th. Mizuho lifted their price target on Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, October 10th. Finally, UBS Group initiated coverage on Harmony Biosciences in a research report on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price target for the company. Two analysts have rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat, Harmony Biosciences currently has an average rating of “Moderate Buy” and an average price target of $44.38.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.